Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance to Participate in Upcoming Virtual Healthcare Conferences

Business Wire May 26, 2021

Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection

Business Wire May 26, 2021

Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update

Business Wire May 10, 2021

Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021

Business Wire May 3, 2021

Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA's 24-Week Long Duration Profile Across Multiple Female Age Cohorts

Business Wire April 27, 2021

Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma

Business Wire April 27, 2021

Revance to Present Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Fillers at American Academy of Dermatology VMX Meeting 2021

Business Wire April 23, 2021

Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference

Business Wire April 6, 2021

Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at the American Academy of Neurology Annual 2021 Virtual Meeting

Business Wire April 1, 2021

Fortune Names Revance to the Top 10 Best Workplaces in Biopharma in 2021

Business Wire March 22, 2021

Revance to Participate in Upcoming Virtual Healthcare Conferences

Business Wire February 24, 2021

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 23, 2021

Revance Reports Fourth Quarter and Full Year 2020 Financial Results

Business Wire February 22, 2021

Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity

Business Wire February 22, 2021

Revance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey O'Connor Kolaja, to its Board of Directors

Business Wire February 22, 2021

Revance to Release Fourth Quarter and Full Year 2020 Financial Results on Monday, February 22, 2021

Business Wire February 12, 2021

Revance to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm for Dermatologists 2021

Business Wire January 25, 2021

Revance Issues Inaugural Environmental, Social and Governance (ESG) Report

Business Wire January 22, 2021

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 19, 2021

Revance to Participate in the 39th Annual J.P. Morgan Healthcare Conference

Business Wire January 7, 2021